Last update April 27, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Тельмизартан is Telmisartan in Cyrillic.
Is written in other languages:Тельмизартан belongs to these groups or families:
Main tradenames from several countries containing Тельмизартан in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 40 - 58 | % |
Molecular weight | 515 | daltons |
Protein Binding | 100 | % |
VD | 6.9 | l/Kg |
pKa | 3.62 | - |
Tmax | 1 - 3 | hours |
T½ | 24 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an angiotensin II receptor antagonist with actions similar to those of losartan. It is indicated in the treatment of hypertension. Oral administration once a day.
At latest update, relevant published data on excretion into breast milk were not found.
Its pharmacokinetic data (very large volume of distribution, moderately high molecular weight and high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.
It is one of the sartanes (ARBs) with the longest half-life and oral bioavailability (Tamargo 2006), making it one of the least indicated during breastfeeding.
Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken Telmisartan during pregnancy. (Pietrement 2003)
Until more data on this medication is available safer alternative drugs are preferred (Malachias 2016, Rowe 2013), especially in premature babies or during the neonatal period.